ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Anti-BCR-ABL drugs, known as tyrosine kinase inhibitors (TKIs), have led to long-term remissions in more than 80% of CML patients and even cure in about one-third of patients.